MeSH tree: D12.776.631.650.300.001
As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights into the rapidly evolving use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as Ozempic ...
May 27, 2025
0
18
A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.
May 23, 2025
0
222
A new analysis being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May), finds that around half of the 100 top TikTok videos about food noise reference the use of medications—mainly the popular ...
May 14, 2025
0
14
New animal research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide treatment, with tirzepatide temporarily increasing ...
May 14, 2025
0
25
A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk's Wegovy.
May 12, 2025
0
34
Weight-loss medications such as Ozempic, Wegovy, and Mounjaro have attracted widespread attention, making headlines across pop culture and scientific sectors alike. But it appears that hearing about these medications is a ...
May 6, 2025
0
22
A recent analysis of the SURPASS-3 trial unravels the impact of treatment with the drug tirzepatide on muscle volume and fat infiltration in individuals with type 2 diabetes.
May 1, 2025
0
105
Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), ...
Apr 30, 2025
0
17
Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the mechanisms of action of tirzepatide—a drug known as Zepbound—on weight loss with respect to energy ...
Apr 24, 2025
0
87
New research being presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that women are much more aware of and knowledgeable about the obesity drugs GLP-1/GIP receptor agonists (that ...
Apr 18, 2025
0
21
